In subcutaneous medulloblastoma xenografts, AG-014699 (1 mg kg−1 i.p.) plus temozolomide (68 mg kg−1 orally), daily for 5 days, produced model-dependent effects. D283Med growth delay changed only from 2 to 2.5 days. D384Med growth delay increased from 28.5 to 46 days, but this difference was not significant (P=0.11). Combination treatment increased body-weight loss relative to temozolomide alone. [1]
AG-014699 with temozolomide in medulloblastoma xenografts
Animal study · Female athymic CD-1 nude mice bearing subcutaneous D425Med, D283Med or D384Med xenografts; five mice per group [1]
Combination efficacy varied by model. D283Med showed little additional growth delay despite cellular sensitization. In D384Med, growth delay increased from 28.5 to 46 days, but the combination benefit was not statistically significant (P=0.11). AG-014699 alone did not materially suppress tumor growth at the tested schedule.
Conditions shared by the study groups
- Frequency
- Once daily
- Treatment course
- 5 days
- Saline control
- Model: Female athymic CD-1 nude mice bearing subcutaneous D425Med, D283Med or D384Med xenografts; five mice per group
- Vehicle: Normal saline
- Reported limits: For D425Med, Table 2 regression counts represent sustained responses; Results reports initial complete regressions in all five TMZ-treated and all five combination-treated mice.
- AG-014699 alone
- Model: Female athymic CD-1 nude mice bearing subcutaneous D425Med, D283Med or D384Med xenografts; five mice per group
- Route: Intraperitoneal
- Vehicle: AG-014699 vehicle not separately specified
- Reported limits: For D425Med, Table 2 regression counts represent sustained responses; Results reports initial complete regressions in all five TMZ-treated and all five combination-treated mice.
- Temozolomide alone
- Model: Female athymic CD-1 nude mice bearing subcutaneous D425Med, D283Med or D384Med xenografts; five mice per group
- Route: Oral
- Vehicle: Temozolomide in saline
- Reported limits: For D425Med, Table 2 regression counts represent sustained responses; Results reports initial complete regressions in all five TMZ-treated and all five combination-treated mice.
- AG-014699 plus temozolomide
- Model: Female athymic CD-1 nude mice bearing subcutaneous D425Med, D283Med or D384Med xenografts; five mice per group
- Route: AG-014699 intraperitoneal; temozolomide oral
- Vehicle: AG-014699 vehicle not separately specified
- Reported limits: For D425Med, Table 2 regression counts represent sustained responses; Results reports initial complete regressions in all five TMZ-treated and all five combination-treated mice.
Methods and source locations
Compound reported in the paper: Rucaparib phosphate (AG-014699); Compound label in the paper: AG-014699
Reported experiments with the phosphate salt; no assertion of Adooq lot validation.
Materials and methods: Materials; Methods: Establishment of D425Med, D283Med and D384Med tumour xenografts; Tumour growth inhibition in vivo; Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts; Table 2
Treatment-associated body-weight loss: Body-weight monitoring; unpaired t-test — Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts, final paragraph
Saline control · Methods: Tumour growth inhibition in vivo; Table 2; Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts
AG-014699 alone · Methods: Tumour growth inhibition in vivo; Table 2; Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts
Temozolomide alone · Methods: Tumour growth inhibition in vivo; Table 2; Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts
AG-014699 plus temozolomide · Methods: Tumour growth inhibition in vivo; Table 2; Results: Efficacy of temozolomide with AG-014699 in human tumour xenografts